The corporation has 5 GMP production workshops, a quality control center, a product research and development (R&D) center, a staff training center and other auxiliary facilities.
Its headquarters are located near Chaoyang North Road, Chaoyang district in Beijing, covering an area of 122,000 sqm.
The corporation has a registered capital of 380.64 million yuan ($60.18 million) and more than 1,300 staff members. It was the first across the country that obtained the national GMP authentication of eight types of medicine. These are tablets, capsules, modest capacity injection tablets, powder injection, sustained-release capsule, gels, transdermal patches, and APIs from seven workshops. In addition, the corporation obtained the ISO9001: 2000 International Quality Management System Authentication and Excellent Award of Beijing Municipal Quality Management in 2001, the ISO14001 Environment Management System Authentication in 2002, the OSHAS18001 (Occupational Safety and Health Administration) in 2004, and the Outstanding Award of Beijing Municipal Quality Management in 2005.
The company now has an effective R&D team of 60 experts, senior consultants and technicians, who have made great contributions to the company. The first emergency contraceptive of China, levonoegestrel tablets (0.75mg), was developed in the R&D lab in 1998.This R&D team has always been one of the most important departments in the company. Every year, over 10 percent of the profit is put aside to build a R&D foundation, which ensures Zizhu is one of the most reliable reproductive health brands in China.
Zizhu regards the motto, "cherish life and promote health," as its business policy for operation and development. Zizhu will commit to enhancing human health as its responsibility, and put utmost care in providing quality products and service to customer.
